Developing new chemical reactions for creating drug candidates
Official title: Sulfur(VI) Fluoride Exchange (SuFEx): new developments and biological applications
Funded at Scripps Research Institute, the · NIH-11017726 · Data updated 2026-11-12
This study is all about making new chemical compounds that could help in finding better treatments for diseases, using special techniques to create a variety of small molecules that scientists will test in the lab and possibly in living organisms.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | February 1, 2024 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $463,680 |
| NIH project number | 5R35GM152118-02 |
| Project ID | NIH-11017726 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from bacterial infections or cancers who may benefit from novel therapeutic agents.
✕Less likely to help
Patients with conditions unrelated to bacterial infections or cancers may not receive any benefit from this research.
What this research studies
This research focuses on creating innovative sulfur fluoride exchange (SuFEx) reactions to build small-molecule libraries that can be used in drug discovery. By utilizing advanced click chemistry techniques, the project aims to generate diverse chemical structures that may have significant biological applications. The researchers will explore how these new compounds function in laboratory settings and potentially in living organisms, which could lead to the development of new treatments for various diseases.
Why it matters
Potential benefit: If successful, this research could lead to the discovery of new drug candidates that effectively target bacterial infections and cancers.
How similar studies have gone: Other research has shown promise with similar chemical approaches, indicating potential for success in this novel application.
Where this research is happening
-
Scripps Research Institute, the
La Jolla, United States Active
Researchers
- Principal investigator: Sharpless, Karl Barry — Scripps Research Institute, the
- Study coordinator: Sharpless, Karl Barry
Related research
Other NIH-funded projects on the same topics.
-
The Participant Center helps people join and stay in a nationwide health study
A nationwide program to support people in joining, contributing biosamples, and staying connected to a large health study in the United States.
-
Data Sharing and Bioinformatics Core for Viral Systems Biology
A center-led effort to manage, share, and interpret large viral systems biology data using open tools and a community-friendly portal.
-
Germline-targeted HIV vaccines using membrane liposome tech to trigger bnAbs
A new HIV vaccine approach aims to spark broadly neutralizing antibodies by showing MPER on membranes, tested in models and early studies to guide future human trials.
-
Antivirals for hemorrhagic fever viruses like LASV, SFTSV, and EBOV
A multi-institutional effort to find and validate antiviral compounds that block key viral proteins from LASV, SFTSV, and EBOV to help people at risk from serious hemorrhagic fevers.
-
Developing new antivirals for flaviviruses
A research team is working to create oral antiviral drugs targeting flaviviruses to treat infections that affect millions of people.
-
CoV inhibitors targeting non-enzymatic SARS-CoV-2 components
A multicenter research effort seeks antiviral ideas that block SARS-CoV-2 parts that don’t work through traditional enzymes, aiming to help people affected by COVID-19.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.